, Plasma cell leukemia. Report on 17 cases, Archives of Internal Medicine, vol.133, issue.5, pp.813-818, 1974.
DOI : 10.1001/archinte.133.5.813
, Plasma cell leukemia: An evaluation of response to therapy, The American Journal of Medicine, vol.83, issue.6, pp.1062-1068, 1987.
DOI : 10.1016/0002-9343(87)90942-9
, Primary plasma cell leukaemia, British Journal of Haematology, vol.82, issue.4, pp.754-759, 1994.
DOI : 10.1002/ajh.2830450315
, Primary plasma cell leukemia: Clinical, immunophenotypic , DNA ploidy, and cytogenetic characteristics, Blood, vol.93, pp.1032-1037, 1999.
, Primary plasma cell leukemia, Cancer, vol.110, issue.24, pp.5734-57391044, 1973.
DOI : 10.1002/cncr.24700
URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.24700/pdf
, Primary plasma cell leukemia: a retrospective multicenter study of 73 patients, Annals of Oncology, vol.95, issue.5, pp.1628-1635, 2011.
DOI : 10.3324/haematol.2009.013334
URL : https://academic.oup.com/annonc/article-pdf/22/7/1628/460712/mdq646.pdf
, Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique, Blood, vol.97, issue.3, pp.822-825, 2001.
DOI : 10.1182/blood.V97.3.822
, Cytogenetic and therapeutic characterization of primary plasma cell leukemia: The IFM experience Genomewide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China Bortezomib is an efficient agent in plasma cell leukemias Efficacy and safety of bortezomib in patients with plasma cell leukemia al: How I treat plasma cell leukemia, Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia 16. D'Arena G, Valentini CG, Pietrantuono G, et al: Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: A retrospective study from GIMEMA Multiple Myeloma Working Party, pp.259-262158, 2005.
, Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.6, pp.1499-1502507, 2011.
DOI : 10.1016/j.clml.2011.06.010
, Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature al: Frequent upregulation of MYC in plasma cell leukemia Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome al: Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia Wholeexome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Leuk Lymphoma Leuk Res Am J Hematol Leuk Lymphoma Am J Hematol Genes Chromosomes Cancer Clin Cancer Res Clin Cancer Res Oncotarget, vol.49, issue.6, pp.2012-20141153, 1999.
, Hospital; Stéphane Minvielle, Institut National de la Santé et de la Recherche Médicale U892, Nantes
, General Hospital, Aix en Provence General Hospital
, All rights reserved, n n n 2132 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY Royer et al Downloaded from ascopubs.org by Institut National de la Sant et de la Recherche Mdicale on, 2018.
, AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www
, Amgen Consulting or Advisory Role: Octapharma Plasma Stéphane Minvielle No relationship to disclose Momar Diouf No relationship to disclose
, Onyx Pharmaceuticals (Inst) Janssen-Cilag (Inst) Travel, Accommodations, Expenses: Celgene, Mundipharma, Hospira, Bristol-Myers Squibb, Sanofi, Janssen-Cilag Lionel Karlin Employment: Laboratoire Aguettant France (I) Honoraria: Celgene, Janssen Pharmaceuticals, Amgen Consulting or Advisory Role Expenses: Celgene Bertrand Arnulf No relationship to disclose Margaret Macro Honoraria: Celgene, Celgene (Inst)
, Accommodations, Expenses: Mundipharma, Spectrum Pharmaceuticals (I)
, Sabine Brechignac No relationship to disclose Karim Belhadj Travel, Accommodations, Expenses: Amgen, Janssen Pharmaceuticals Celgene
, Novartis, Bristol-Myers Squibb Laurent Frenzel No relationship to disclose Laurent Garderet Honoraria: Bristol-Myers Squibb Consulting or Advisory Role: Bristol-Myers Squibb, Amgen Sylvain Choquet Consulting or Advisory Role: Janssen, Celgene Jean Gabriel Fuzibet No relationship to disclose Charles Dauriac No relationship to disclose Luc-Matthieu Forneker Consulting or Advisory Role: Roche, Takeda Pharmaceuticals, Gilead Sciences Speakers' Bureau: Mundipharma Travel, Accommodations, Expenses: Roche, Gilead Sciences, Mundipharma Lotfi Benboubker Consulting or Advisory Role: Celgene Thierry Facon Consulting or Advisory Role, Bureau: Celgene, Janssen Philippe Moreau Consulting or Advisory Role: Celgene, Takeda Pharmaceuticals